Squarepoint Ops LLC Purchases 86,064 Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)

Squarepoint Ops LLC boosted its position in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) by 712.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 98,144 shares of the company's stock after purchasing an additional 86,064 shares during the period. Squarepoint Ops LLC owned about 0.15% of Corvus Pharmaceuticals worth $525,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Sphera Funds Management LTD. bought a new position in shares of Corvus Pharmaceuticals in the fourth quarter worth $2,678,000. RTW Investments LP bought a new position in shares of Corvus Pharmaceuticals in the fourth quarter worth $14,335,000. Man Group plc bought a new position in shares of Corvus Pharmaceuticals in the fourth quarter worth $73,000. OMERS ADMINISTRATION Corp bought a new position in shares of Corvus Pharmaceuticals in the fourth quarter worth $404,000. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in shares of Corvus Pharmaceuticals in the fourth quarter worth $214,000. Hedge funds and other institutional investors own 46.64% of the company's stock.

Corvus Pharmaceuticals Stock Performance

Shares of NASDAQ CRVS remained flat at $3.91 on Friday. 757,443 shares of the company's stock were exchanged, compared to its average volume of 750,149. Corvus Pharmaceuticals, Inc. has a fifty-two week low of $1.75 and a fifty-two week high of $10.00. The company has a 50 day moving average of $3.47 and a 200 day moving average of $4.75. The stock has a market cap of $266.54 million, a P/E ratio of -4.20 and a beta of 0.57.

Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.13) earnings per share for the quarter, meeting the consensus estimate of ($0.13). Analysts expect that Corvus Pharmaceuticals, Inc. will post -0.63 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. Mizuho set a $11.00 price target on shares of Corvus Pharmaceuticals and gave the stock an "outperform" rating in a report on Tuesday, May 20th. Wall Street Zen lowered shares of Corvus Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Tuesday, May 20th. HC Wainwright reiterated a "buy" rating and issued a $11.00 target price on shares of Corvus Pharmaceuticals in a research report on Wednesday, March 26th. Finally, Oppenheimer reissued an "outperform" rating and issued a $17.00 price target (up from $15.00) on shares of Corvus Pharmaceuticals in a research note on Friday, May 9th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $15.00.

Corvus Pharmaceuticals Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.